Petal announces additional investment as momentum builds around incisionless surgery.
For centuries now, surgery has been about invasive and painful manipulation of tissue with one or more tools. Even the most recent advances in the field have not been able to break this fundamental constraint. Petal is changing that. We are developing a new approach to surgery using acoustic liquefaction — delivered through a unique form of histotripsy called Millisecond Pulse Histotripsy — combined with AI and robotics.
We call it incisionless surgery: a new standard of care that eliminates cutting, pain, trauma, and many of the risks inherent to traditional surgery. No cuts. No burns. No toxicity. Then the body heals itself naturally.
Since coming out of stealth in October 2025, momentum around our vision has continued to build.
Today, we are announcing additional investment as investor demand continues following our oversubscribed Series A in 2025, bringing our total funding to over $25M to date. This financing is led by a prominent high net worth investment firm, with repeat participation from Draper Associates, Actions Capital (formerly K50 Ventures), and Fong’s Family Foundation.
The round also coincides with another major milestone for the company: we are honored to share that Dr. Frederic H. Moll, a pioneer of surgical robotics, has joined our Board of Directors, further strengthening our leadership as we advance our approach to incisionless surgery.
“The companies we back are building technologies that sound futuristic — until they suddenly become foundational. They are grounded in real science and engineering, with transformative applications likely to arrive faster than most people expect. Petal is one of those missions. By making surgery incisionless — no cuts, no heat, no toxicity — the body can heal itself naturally. We’re excited to support a future where healing doesn’t begin with harm and where everyone has dignified access to world-class healthcare.”
— Tim Draper, Founder of Draper Associates, Draper University, and the Draper Venture Network.
This additional funding will accelerate our path to patients through focused research and development and the continued recruitment of world-class talent.
“Prash lost his father to surgical complications. That loss became a mission — and that mission became Petal. From the moment we met him, it was clear he wasn’t building an incremental improvement — he was starting over. Three investments later, we’re more convinced than ever that he is the right person to lead the team that will make incisionless surgery the new standard of care.” — Ryan Bloomer, Founder, Actions Capital (formerly K50 Ventures).
We’re excited to see continued support of our human-centric approach to healthcare. We envision a world where incisionless surgery becomes the standard of care, accessible to patients in all communities — modern and developing — while eliminating many of the risks and complications associated with traditional surgery.
We invite you to stay close, as there will be more from us in the coming months. Please follow us on LinkedIn, Twitter/X, and Instagram.
About Petal
Petal Surgical is pioneering a new field of incisionless surgery through Millisecond Pulse Histotripsy, combined with robotics and AI. The company has raised over $25M to date, including an oversubscribed Series A in 2025 co-led by K50 Ventures and TSVC, with participation from ShangBay Capital and Dr. Frederic H. Moll. A subsequent financing was led by a prominent high-net-worth investment firm, with repeat participation from Draper Associates, Actions Capital, and Fong’s Family Foundation.
Founded by Prash Chopra (image-guided surgery engineer), Dr. Bowen Jiang (neurosurgeon), Dr. Nicholas Theodore (robotic-assisted spine surgery pioneer), and Rony Abovitz (Founder of MAKO Surgical, SynthBee, and MagicLeap), Petal is advancing a safer, incisionless future for surgery worldwide.